Technical Analysis for MRNA - Moderna, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
19.0 | -1.76% | -0.34 |
MRNA closed down 1.76 percent on Friday, March 22, 2019, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | N/A | Up | Down |
| See historical MRNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 22 | New Downtrend | Bearish | 0.00% |
| Mar 22 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% |
| Mar 22 | NR7 | Range Contraction | 0.00% |
| Mar 22 | Down 3 Days in a Row | Weakness | 0.00% |
| Mar 22 | Down 4 Days in a Row | Weakness | 0.00% |
| Mar 22 | Oversold Stochastic | Weakness | 0.00% |
| Mar 21 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -1.76% |
| Mar 21 | Stochastic Reached Oversold | Weakness | -1.76% |
| Mar 21 | Multiple of Ten Bearish | Other | -1.76% |
| Mar 21 | Down 3 Days in a Row | Weakness | -1.76% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-06
Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Cancer Life Sciences Biology RNA Messenger RNA
Cancer Life Sciences Biology RNA Messenger RNA
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MRNA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 24.4 |
| 52 Week Low | 13.03 |
| Average Volume | 946,458 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 18.7252 |
| 20-Day Moving Average | 21.007 |
| 10-Day Moving Average | 20.317 |
| Average True Range | 1.3719 |
| ADX | 27.92 |
| +DI | 19.1452 |
| -DI | 20.514 |
| Chandelier Exit (Long, 3 ATRs ) | 20.2843 |
| Chandelier Exit (Short, 3 ATRs ) | 22.8657 |
| Upper Bollinger Band | 23.3826 |
| Lower Bollinger Band | 18.6314 |
| Percent B (%b) | 0.08 |
| BandWidth | 22.617223 |
| MACD Line | 0.1982 |
| MACD Signal Line | 0.5568 |
| MACD Histogram | -0.3586 |
| Fundamentals | Value |
|---|---|
| Market Cap | 173.58 Million |
| Num Shares | 9.14 Million |
| EPS | -3.84 |
| Price-to-Earnings (P/E) Ratio | -4.95 |
| Price-to-Sales | 4.85 |
| Price-to-Book | 0.47 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 20.43 | ||||
| Resistance 3 (R3) | 20.50 | 20.10 | 20.19 | ||
| Resistance 2 (R2) | 20.10 | 19.74 | 20.06 | 20.11 | |
| Resistance 1 (R1) | 19.55 | 19.51 | 19.35 | 19.48 | 20.03 |
| Pivot Point | 19.15 | 19.15 | 19.05 | 19.11 | 19.15 |
| Support 1 (S1) | 18.60 | 18.79 | 18.40 | 18.53 | 17.97 |
| Support 2 (S2) | 18.20 | 18.56 | 18.16 | 17.89 | |
| Support 3 (S3) | 17.65 | 18.20 | 17.81 | ||
| Support 4 (S4) | 17.58 |
